But the surge in Chinese pharma is still ringing alarm bells. “China’s rise in biotech is a threat to the United States,” ...

Stifel Financial Corp. SF reported key operating results as of May 31, 2025, highlighting year-over-year increases in client ...

A Relative Strength Rating upgrade for Stifel Financial shows improving technical performance. Will it continue?

The FDA found that data from a single Phase II study were “insufficient” to justify an accelerated approval review for ...